Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Feb 10;43(5):498-504.
doi: 10.1200/JCO-24-01785. Epub 2024 Dec 4.

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis

Eric M Jurgens  1 , Ross S Firestone  1 , Jagrutiben Chaudhari  2 , Kinga Hosszu  3 , Sean M Devlin  4 , Urvi A Shah  1 , Jonathan Landa  5 , Devin P McAvoy  3 , Alexander M Lesokhin  1   6 , Neha Korde  1 , Hani Hassoun  1 , Carlyn R Tan  1 , Malin Hultcrantz  1 , Gunjan L Shah  6   7 , Heather J Landau  6   7 , David J Chung  6   7 , Michael Scordo  6   7 , Ozgur Can Eren  8 , Ahmet Dogan  8 , Sergio A Giralt  6   7 , Jae H Park  6   9 , Isabelle Rivière  2 , Renier J Brentjens  10 , Eric L Smith  11 , Xiuyan Wang  2 , Saad Z Usmani  1   6   7 , Sham Mailankody  1   6
Affiliations
Clinical Trial

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis

Eric M Jurgens et al. J Clin Oncol. .

Abstract

MCARH109 is a first-in-class G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 × 106 CAR T cells. In this updated analysis, no new serious adverse events were reported at a median follow-up of 37 months. Overall, 12 (71%) of 17 patients responded, including seven (70%) of 10 patients previously treated with B-cell maturation antigen-targeted therapy. The median duration of response was 8.6 months (95% CI, 5.7 to not reached [NR]) with two patients sustaining a stringent complete response at the time of last follow-up, 32 months and 41 months, respectively. The median overall survival (OS) was NR and the 3-year OS estimate was 59% (95% CI, 40 to 88). Possible GPRC5D loss via immunohistochemistry was observed in 6 (60%) of 10 patients at relapse. High-dimensional spectral cytometry-based immune profiling associated an activated T-cell phenotype at apheresis with a response to MCARH109.

Trial registration: ClinicalTrials.gov NCT04555551.

PubMed Disclaimer

References

    1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al.: Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine 388:1002–1014, 2023 - PubMed
    1. Anderson JLD, Munshi NC, Shah N, et al.: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. Journal of Clinical Oncology 39:8016–8016, 2021
    1. San-Miguel J, Dhakal B, Yong K, et al.: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. New England Journal of Medicine, 2023 - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al.: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet 398:314–324, 2021 - PubMed
    1. Johnson J: CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy, 2024

Publication types

Substances

Associated data